Reading PGEN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PGEN free→Reading PGEN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PGEN free→QuarterlyIQ Insights · PGEN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 13, 2026, reporting its financial results for the quarter ended March 31, 2026. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth…
Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 25, 2026, reporting its financial results for the year ended December 31, 2025. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set for…
Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated November 13, 2025, reporting its financial results for the quarter ended September 30, 2025. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly…
Unregistered Sales of Equity Securities. On September 15, 2025, the holders of Precigen, Inc.’s (the “Company’s” and “our”) 8.00% Series A Convertible Perpetual Preferred Stock (“Preferred Stock”) converted 79,000 shares of Preferred Stock (with an aggregate stated value of $79,000,000) into 54,937,411 shares of common stock of the Company, which were delivered to such holders on September 17, 2025 pursuant to the terms of our Amended and Restated Articles of Incorporation and such Preferred…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Entry into a Material Definitive Agreement. Pharmakon Loan Agreement On September 3, 2025 (the “ Closing Date ”), Precigen, Inc . (“ we ” or the “ Company ”) and certain of our subsidiaries party thereto as guarantors entered into a loan agreement (the “ Loan Agreement ”) with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership as the lenders thereunder (the “ Lenders ”) and BioPharma Credit PLC as the collateral agent, each of which are investment entities managed by Phar…
Entry into a Material Definitive Agreement. On August 13, 2025 (the “Effective Date”), Precigen, Inc. (the “Company”) entered into a Commercial Supply Agreement (the “Supply Agreement”) with Catalent Maryland, Inc. (“Catalent”). The Supply Agreement provides that Catalent will perform certain services specified in a Plan Document (as defined in the Supply Agreement) (“Services”) including analytical, development, processing, validation, or product maintenance of PAPIZEMOS (“Product”), subject…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the Annual Meeting of Stockholders of Precigen, Inc. (the “Company”) held on June 26, 2025 (the “2025 Annual Meeting”), the Company’s stockholders approved an amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan, as amended (the “2023 Plan”), to increase the number of shares of common stock available for issuance thereunder by 11.5 millio…
Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 14, 2025, reporting its financial results for the quarter ended March 31, 2025. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth…
Results of Operations and Financial Condition. Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 19, 2025, reporting its financial results for the quarter and year ended December 31, 2024. This information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expre…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.